Sign in
Taking peopleEarly phase 1

Vitamin D3 for women with uterine fibroids and low vitamin D

Tests vitamin D3 in women with symptomatic uterine fibroids and low vitamin D.

Key facts

Who runs it
Nahida Akter
Where
Bangladesh1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Effect of Vitamin D3 Supplementation on Symptomatic Uterine Fibroid in Women With Vitamin D Deficiency
Status
Recruiting
Phase
Early phase 1
People taking part
39 people, planned
Started
20 Feb 2025
Planned end
Sept 2026
Type of study
Interventional
Treatments tested
  • Colecalciferol (Vitamin D3) 50000 UI
Record updated
10 June 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with uterine fibroids that cause symptoms and who have low vitamin D. Uterine fibroids are non-cancer growths in the womb. Women in the trial take vitamin D3 by mouth for 6 months.

Age
18 to 50 years
Sex
Women only
Disease stage
Uterine fibroids (leiomyoma) confirmed by ultrasound, with symptoms. Symptoms include heavy menstrual bleeding or symptoms from the fibroid's size, such as needing to pass urine often.
Earlier treatment
You cannot be using hormonal therapy, other vitamin D supplements, or medicines that affect calcium or fibroid growth (e.g., GnRH agonists, anti-estrogens). You cannot have had surgery (e.g., myomectomy, hysterectomy) or other medical treatment for fibroids in the past 6 months.
Biomarker or test result
Blood level of 25-hydroxyvitamin D [25(OH)D] below 20 ng/mL (vitamin D deficiency).

Main reasons for not taking part

  • Pregnant or breastfeeding, or planning to get pregnant during the study
  • Long-term illnesses such as autoimmune diseases, cancers, or severe liver or kidney disease
  • Hyperparathyroidism or other calcium disorders
  • Current or recent hormonal therapy or vitamin D supplements
  • Surgery or other medical treatment for fibroids in the past 6 months

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • .Women aged between 18-50 not currently pregnant, lactating, or planning to conceive during the study period
  • Women with a confirmed diagnosis of uterine fibroids (leiomyoma) through ultrasound
  • Serum 25-hydroxyvitamin D [25(OH)D] levels below 20 ng/mL (indicating vitamin D deficiency)
  • Presence of symptoms associated with uterine fibroid, such as menorrhagia (heavy menstrual bleeding), or bulk-related symptoms (e.g., urinary frequency)
  • Participants should be generally healthy, with no history of other chronic illnesses that could affect the study's outcomes (e.g., autoimmune diseases, cancers, severe liver or kidney diseases)
  • Willingness to provide written informed consent for participation in the study
  • No current use of hormonal therapy, other vitamin D supplements, or medications known to influence calcium metabolism or uterine fibroid growth (e.g., GnRH agonists, anti-estrogens)
  • Participants must be willing and able to adhere to the study protocol, including attending follow-up visits and completing any required assessments or tests

Who cannot take part

  • Women who have undergone surgical interventions (e.g., myomectomy, hysterectomy) or other medical treatments specifically for uterine fibroid within the past 6 months
  • Presence of chronic illnesses such as autoimmune diseases, cancers, or severe liver or kidney disease that could interfere with the study's outcomes
  • Serum 25-hydroxyvitamin D [25(OH)D] levels of 20 ng/mL or higher
  • Current or recent use of hormonal therapy, other vitamin D supplements, or medications that affect calcium metabolism or uterine fibroid growth (e.g., GnRH agonists, anti-estrogens)
  • Women with conditions like hyperparathyroidism or calcium disorders that might affect vitamin D metabolism or fibroid growth
  • Women younger than 18 or older than 50 years
  • Women without a confirmed diagnosis of uterine fibroids (leiomyoma) through imaging
  • Pregnant or breastfeeding women, or those planning to conceive during the study period

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 50 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

39 women with symptomatic uterine fibroid with serum vitamin D deficiency will receive vitamin D3 supplementation for 6 month.then symptoms and size of fibroid will be re evaluated..

The group in the trial

  • Pt with uterine fibroidTreatment being tested

    Study subjects will be selected according to inclusion and exclusion criteria, consents will be taken in informed written consent form, and then preceded as follow- 39 diagnosed women with uterine fibroid aged 18 to 50 years experiencing heavy menstrual bleeding will be purposively selected upon meeting the selection criteria Demographic information, medical history, clinical examination findings, and other relevant clinical data will be gathered through interviews Baseline Assessments: menstrual blood loss, hemoglobin concentration and ultrasound parameters (uterine volume, fibroid characteristics) Participants received 25(OH) Vitamin D3 orally

    Treatment: Colecalciferol (Vitamin D3) 50000 UI

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Vitamin D3 Supplementation on Symptomatic Uterine Fibroid in Women With Vitamin D Deficiency
Plain-language title
Vitamin D3 for women with uterine fibroids and low vitamin DGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT07012161, who can take part
Record updated
10 June 2025